Holen Sie sich die Stockscreener-App
23.06
1.27%
0.29
Handel nachbörslich:
23.02
-0.04
-0.17%
Schlusskurs vom Vortag:
$22.77
Offen:
$22.8
24-Stunden-Volumen:
1.37M
Relative Volume:
0.40
Marktkapitalisierung:
$4.26B
Einnahmen:
$637.78M
Nettoeinkommen (Verlust:
$239.40M
KGV:
19.36
EPS:
1.1909
Netto-Cashflow:
$307.21M
1W Leistung:
-2.82%
1M Leistung:
-9.00%
6M Leistung:
-68.30%
1J Leistung:
-55.00%
1-Tages-Spanne:
$22.65
$23.20
1-Wochen-Bereich:
$21.82
$24.09
52-Wochen-Spanne:
$21.82
$76.51
Doximity Inc Stock (DOCS) Company Profile
Firmenname
Doximity Inc
Sektor
Branche
Telefon
(650) 549-4330
Adresse
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Compare DOCS vs VEEV, TEM, BTSG, HQY, WAY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
23.06 | 4.21B | 637.78M | 239.40M | 307.21M | 1.1909 |
VEEV
Veeva Systems Inc
|
174.64 | 28.42B | 3.20B | 908.91M | 1.39B | 5.4168 |
TEM
Tempus Ai Inc
|
47.30 | 8.47B | 1.27B | -245.03M | -245.36M | -1.4071 |
BTSG
Brightspring Health Services Inc
|
43.51 | 8.28B | 12.91B | 104.80M | 394.69M | 0.8769 |
HQY
Healthequity Inc
|
83.44 | 7.15B | 1.31B | 215.20M | 408.32M | 2.4627 |
WAY
Waystar Holding Corp
|
23.63 | 4.55B | 1.10B | 112.09M | 283.19M | 0.6096 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2026-02-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2026-01-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-01-08 | Hochstufung | Truist | Hold → Buy |
| 2025-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-10-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-01 | Herabstufung | Goldman | Neutral → Sell |
| 2025-07-09 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-02-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-15 | Eingeleitet | Goldman | Neutral |
| 2024-11-14 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Hochstufung | Needham | Hold → Buy |
| 2024-07-18 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2024-01-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-08-09 | Herabstufung | Needham | Buy → Hold |
| 2023-08-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-24 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-13 | Eingeleitet | BTIG Research | Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Eingeleitet | Berenberg | Buy |
| 2022-05-18 | Bestätigt | BofA Securities | Neutral |
| 2022-05-18 | Bestätigt | Goldman | Buy |
| 2022-05-18 | Bestätigt | Guggenheim | Buy |
| 2022-05-18 | Bestätigt | Jefferies | Buy |
| 2022-05-18 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Bestätigt | Needham | Buy |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-04 | Eingeleitet | BofA Securities | Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-10 | Bestätigt | Canaccord Genuity | Buy |
| 2021-11-10 | Bestätigt | Goldman | Neutral |
| 2021-11-10 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Bestätigt | Needham | Buy |
| 2021-11-10 | Bestätigt | Piper Sandler | Overweight |
| 2021-08-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-19 | Eingeleitet | Goldman | Neutral |
| 2021-07-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-19 | Eingeleitet | Raymond James | Outperform |
| 2021-07-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Doximity Inc Aktie (DOCS) Neueste Nachrichten
Doximity IPO: Everything you need to know about Doximit - FOREX.com
Doximity, Inc. (DOCS) stock price, news, quote and history - Yahoo Finance UK
Doximity, Inc. (DOCS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Doximity Sits 70% Below Its 52-Week High With 300,000 AI Users and Zero AI Revenue - TIKR.com
Doximity Analyst Ratings and Price Targets | NYSE:DOCS - Benzinga
DOCS PE Ratio & Valuation, Is DOCS Overvalued - Intellectia AI
TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now? - The Globe and Mail
Doximity (NYSE:DOCS) Reaches New 12-Month LowWhat's Next? - MarketBeat
Doximity, Inc. Stock Hits New 52-Week Low at $23.14 - Markets Mojo
Has Doximity (DOCS) Become Attractive After Its Sharp Share Price Pullback? - Yahoo Finance
Does Doximity’s (DOCS) Scale With Physicians and Cash Flow Redefine Its Healthcare Tech Moat? - simplywall.st
DOCS Technical Analysis & Stock Price Forecast - Intellectia AI
HIMS vs. DOCS: Which digital health stock offers better upside now? - MSN
Doximity downgraded at J.P. Morgan on valuation and advertising concerns - msn.com
Fort Washington Investment Advisors Inc. OH Purchases 231,790 Shares of Doximity, Inc. $DOCS - MarketBeat
Fort Washington Investment Advisors Boosts Doximity Stake by Over 100% - National Today
Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Freedom Capital initiates Doximity (DOCS) with buy rating, $31 price target - msn.com
Doximity $31 Million Securities Class Action Settlement - Claim Depot
Vanguard reorganizes reporting; affiliates to report DOCS holdings (DOCS) - Stock Titan
Doximity Declines 4.4% in a Month: How to Play the Stock Now? - msn.com
Doximity, Inc. (NYSE:DOCS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Doximity, Inc. (DOCS) Stock Forecasts - Yahoo Finance
Fidelity Trend Fund's Doximity Inc(DOCS) Holding History - GuruFocus
Doximity (NYSE:DOCS) Hits New 1-Year LowTime to Sell? - MarketBeat
HIMS or DOCS: Which Digital Health Company Has Greater Growth Potential Today? - Bitget
Doximity stock hits 52-week low at 23.53 USD By Investing.com - Investing.com South Africa
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now? - The Globe and Mail
Doximity stock hits 52-week low at 23.53 USD - Investing.com
E. Ohman J or Asset Management AB Invests $24.70 Million in Doximity, Inc. $DOCS - MarketBeat
Hims & Hers Expands Integrated Digital Healthcare Ecosystem - TradingView
Freedom Capital Initiates Doximity (DOCS) With Buy Rating, $31 Price Target - Insider Monkey
Doximity Inc. (NYSE:DOCS) Presents a Compelling Case for Growth at a Reasonable Price (GARP) Investors - ChartMill
Doximity (NYSE:DOCS) Upgraded to "Strong-Buy" at Freedom Capital - MarketBeat
The Bull Case For Doximity (DOCS) Could Change Following Surge In Physician AI Interest And Concerns - sahmcapital.com
Doximity (DOCS) Receives "Buy" Rating from Freedom Capital Marke - GuruFocus
Analysts Offer Insights on Healthcare Companies: Canopy Growth (CGC) and Doximity (DOCS) - The Globe and Mail
Raymond James sees ‘knee-jerk’ AI reaction, reaffirms strong buy on Doximity, Inc. (DOCS) - MSN
Physicians still concerned about AI accuracy amid rapid adoption: survey - Healthcare Dive
Doximity stock is collapsing after hours: Here's why - MSN
A Look At Doximity’s Valuation After New Report On Rapid Physician AI Adoption - simplywall.st
Freedom Capital Markets initiates Doximity stock with buy rating By Investing.com - Investing.com Australia
Freedom Capital Markets initiates Doximity stock with buy rating - Investing.com
SEC files settled insider trading charges against former Chief Revenue Officer of Doximity - fxnewsgroup.com
Doximity Study Finds Physicians Rapidly Adopting AI, But Accuracy Concerns Persist - The AI Journal
Aquatic Capital Management Buys Doximity Shares - National Today
Finanzdaten der Doximity Inc-Aktie (DOCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.46%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):